Company Analysis
Sign in

Incyte Corp. (INCY)

Nasdaq: INCY · Services-Commercial Physical & Biological Research · Wilmington, DE · filing with the SEC since 1994
Full chart Alerts Compare
Grade7.5
◀ Past 7.7● Present 7.1▶ Future 7.8
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,430 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Incyte Corp.’s names, not what it holds today.

Patents granted
1,430
1,430 utility, 1976 to Dec 31, 2025
Granted in 2025
50
Against 68 in 2024 and 58 in 2023
Applications published
1,157
86 of them in 2025
Names they are printed under
7
its own name, a former name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry137
Pharmaceuticals132
Analysis of biological materials3
Biotechnology2
Furniture, games1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
Incyte Corporation its own name
US, as the owner printed on each patent
676 granted
276 published
Incyte Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
579 granted
111 published
Incyte Corporation its own name
named as the applicant on its applications, in US. 8 more under the same name are not counted (printed in DE)
0 granted
657 published
Incyte Genomics, Inc. a former name
US, as the owner printed on each patent
163 granted
88 published
Escient Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
23 published
Escient Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
12 granted
0 published
Villaris Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Names not counted (2)
Incyte Holdings Corporation
Every patent under it that falls to this company prints another country (DE). 0 granted and 128 published under it are not counted.
INCYTE CORP
No country is printed for it. 0 granted and 12 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,498,382Biomarkers for vitiligoAnalysis of biological materialsIncyte Corporation
Dec 9, 202512,491,244Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cellPharmaceuticalsIncyte Corporation
Nov 25, 202512,479,851Process and intermediates for preparing a JAK inhibitorOrganic fine chemistryIncyte Corporation
Nov 18, 202512,473,286Salts of an FGFR inhibitorOrganic fine chemistryIncyte Corporation
Nov 11, 202512,466,828Bicyclic amines as CDK2 inhibitorsOrganic fine chemistryIncyte Corporation
Nov 11, 202512,466,822Heterocyclic compounds as immunomodulatorsOrganic fine chemistryIncyte Corporation
Nov 11, 202512,466,815Carboxamide compounds and uses thereofOrganic fine chemistryIncyte Corporation
Nov 4, 202512,459,943Crystalline solid forms of a BET inhibitorPharmaceuticalsIncyte Corporation
Oct 21, 202512,448,448Anti-PD-1 antibodies and uses thereofPharmaceuticalsIncyte Corporation
Oct 14, 202512,441,742Naphthyridine compounds as inhibitors of KRASOrganic fine chemistryIncyte Corporation
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388691METHODS FOR TREATING LYMPHOMABiotechnologyIncyte Corporation
Dec 25, 20252025/0388553AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORSOrganic fine chemistryIncyte Corporation
Dec 25, 20252025/0387401FORMULATIONS OF AN AXL/MER INHIBITORPharmaceuticalsIncyte Corporation
Dec 4, 20252025/0368641QUINOLINE COMPOUNDS AS INHIBITORS OF KRASPharmaceuticalsIncyte Corporation
Dec 4, 20252025/0367202JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERSPharmaceuticalsIncyte Corporation
Nov 20, 20252025/0353842BICYCLIC AMINE CDK12 INHIBITORSOrganic fine chemistryIncyte Corporation
Nov 13, 20252025/0345338RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITISPharmaceuticalsIncyte Corporation
Nov 13, 20252025/0345337TOPICAL FORMULATION FOR A JAK INHIBITORPharmaceuticalsIncyte Corporation
Nov 6, 20252025/0340559PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDSOrganic fine chemistryIncyte Corporation
Oct 30, 20252025/0333420FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORSOrganic fine chemistryIncyte Corporation
What it applied for, 2024 to 2025: Pharmaceuticals 91 · Organic fine chemistry 68 · Biotechnology 5 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton INCY · research, not advice